

1 **Supplementary materials to Papp et al. “Rucaparib blocks SARS-CoV-2 virus binding to**
2 **cells and interleukin-6 release in a model of COVID-19”**

3
4 **Supplementary methods**

5 *Chemicals*

6 Rucaparib was a generous gift from Dr. Thomas Harding (Clovis Oncology, Boulder, CO,
7 USA), while Talazoparib and Olaparib was purchased from Sigma (St. Louis, MO, USA) and
8 Stenoparib was from Selleckchem (Houston, TX, USA). LPS was from Sigma (St. Louis, MO,
9 USA Cat. No: L4516), while the spike protein used to induce macrophages was from Merck
10 (Kenilworth, NJ, USA, Cat. No.:AGX818).

11
12 *COVID-19 Patients*

13 Formalin-fixed, paraffin embedded (FFPE) blocks of patients was assessed who died of
14 COVID-19 at Szent Erzsébet Hospital (Sátoraljaújhely, Hungary) between 30th November 2020
15 – 6th February 2021. Controls were patients died of non-COVID-19 causes. Controls were
16 selected from patients died in the same period of non-COVID-19 and not lung-related causes
17 at the clinical units of the University of Debrecen. Demographics of the patients are in
18 **Supplementary Table 1**. We excluded patients with nosocomial infections in their records.
19 The study was authorized by the local ethical board (6043/2022).

20
21 *Blood donors*

22 Monocytes were prepared from buffy coat of healthy donors. The study was authorized by the
23 local ethical board (Reg. No. 938-2/2014/5200). Three-three donors were used in the LPS-
24 induction and spike-induction experiments.

25
26 *Immunohistochemistry for poly(ADP-ribose), 4-hydroxynonenal (HNE) and spike protein*

27 Five micron thick sections were obtained from formalin-fixed, paraffin embedded blocks of
28 COVID-19 patients. Immunohistochemistry was performed as in^{1,2} with the conditions in
29 **Supplementary Table 2**.

30
31 *Cell culture*

32 Vero E6 cells were cultured at 37 °C, 5% CO₂ in DMEM supplemented with 10% FBS and 1%
33 penicillin-streptomycin.

34 Human embryonic kidney cells (HEK-293T) cells expressing ACE2 receptor and the
35 TMPRSS2 protease (GeneCopoeia, Rockville, MD, USA) were grown in DMEM supplemented
36 with 10 % FBS, and selection antibiotics (hygromycin 100 µg/mL, puromycin 1 µg/mL) and
37 maintained in 37 C, 5% CO₂ incubator.

38 A549 lung adenocarcinoma constitutively expressing FLAG-tagged SARS-CoV-2 Nsp3
39 macrodomain or its control empty vector³ were grown in DMEM/high glucose media (Thermo)
40 supplemented with 10% Fetal Bovine Serum (Thermo) and maintained at 37°C in a humidified
41 atmosphere containing 5% CO₂.

42

43 *Viruses*

44 SARS-CoV-2 B.1.5 (Accession ID: EPI_ISL_483637, with D614G mutation), B.1.1.7.
45 (Accession ID: EPI_ISL_826270) and B.1.617.2 (Accession ID: EPI_ISL_9625925) variants
46 were isolated at the National Laboratory of Virology (University of Pécs, Pécs, Hungary).
47 Variants were verified by sequencing.

48 SARS-CoV-2 spike protein-pseudotyped lentivirions were produced by transfection of HEK-
49 293T cells with the following plasmids: pLenti CMV GFP Puro expression vector, psPAX2
50 packaging plasmid (Addgene, Watertown, MA, USA), and pcDNA3.1 plasmids coding for either
51 the Wuhan-Hu-1 prototypical, the 1.617 or the 1.351 SARS-CoV-2 spike variant (GenScript
52 Biotech, Piscataway NJ, USA). Transfection was done in a 1:1:1 ratio using the
53 polyethylenimine (PEI) method, and virion production was carried out as described previously
54 ⁴. Following collection and concentration of the pseudovirions, an enzyme-linked
55 immunosorbent assay (ELISA)-based colorimetric reverse transcriptase (RT) assay (Roche
56 Applied Science, Mannheim, Germany) was then used to detect the amount of RT in the virus
57 samples, and transduction (infection) of cells was carried out using 4 ng RT-equivalent of the
58 pseudovirions (MOI 0.2).

59

60 *Virus proliferation assay*

61 In a 96-well cell culture plate, 3x 10⁵ Vero E6 cells were seeded on the previous day of the
62 infection. Treatment with the different PARP inhibitors (eucaparib, olaparib, talazoparib) from
63 40 – 2.5 µM were done at the same time with the infection of SARS-CoV-2 (Accession ID:
64 EPI_ISL_483637, B.1.5 variant) at MOI 0.01 in a BSL-4 laboratory. After a 30 minutes of
65 incubation in a cell culture CO₂ incubator, the mixture of the virus and the compound was
66 replaced with only compound containing cell culture media (DMEM, 2% HI FBS, 1% PS). 48
67 hours post infection the supernatant was collected. RNA extraction was performed using the
68 Monarch Total RNA miniprep kit (New England Biolabs, Ipswich, MD, USA). Viral titer from
69 the supernatant was determined using a QX200 AduToDG Droplet- Digital PCR using the
70 ddPCR Supermix (both from Bio-Rad, Hercules, CA, USA). The PCR was specific for the
71 SARS-CoV-2 RdRp gene (forward primer: GTGARATGGTCATGTGTGGCGG; reverse:
72 CARATGTTAAASACACTATTAGCATA, probe FAM-CAGGTGGAACCTCATCAGGAGATGC-
73 BBQ). IC₅₀ was determined by performing a non-linear regression using the [Inhibitor] vs.

74 response variable slope (four parameters) macro of Graphpad Prism. For rucaparib the R2
75 value was $R^2_{infection}=0.8176$.

76

77 *Viability assays*

78 Cell viability was assessed in Vero E6 cells using the CellTiter-Glo assay (Promega, Madison,
79 WI, USA). IC₅₀ was determined by performing a non-linear regression using the [Inhibitor] vs.
80 response variable slope (four parameters) macro of Graphpad Prism. The R² value for the
81 goodness of fit was $R^2_{viability}=0.9776$ for Rucaparib.

82

83 *Neutralization assay on Vero E6 cells*

84 8×10^5 Vero E6 cells were seeded in a 48-well plate. The next day the plate was transferred
85 to the BSL-4 laboratory. SARS-CoV-2 B.1.1.7 viral stocks were diluted to 0.01 MOI in DMEM
86 (Lonza, Basel, Switzerland). Virus suspension (25 μ l) was mixed with 25 μ l rucaparib (60, 44
87 and 10 μ M diluted in DMEM) and incubated for an hour at room temperature. After the
88 incubation period 450 μ l DMEM was added to the mixture then it was added to the cells. The
89 cells were infected for 30 min at 37 °C. The SARS-CoV-2 and rucaparib mixture was then
90 discarded and the cells were incubated for 2 days with DMEM supplemented with 2% HI FBS
91 and 1% Pen-Strep. 48 hours post infection the supernatant was collected. RNA extraction was
92 performed using the EXM 3000 nucleic acid isolation system (Zybio, Chongqing, China). Viral
93 titer from the supernatant was determined using a QX200 AdutoDG Droplet- Digital PCR using
94 the ddPCR Supermix (both from Bio-Rad, Hercules, CA, USA). The PCR was specific for the
95 SARS-CoV-2 RdRp gene (forward primer: GTGARATGGTCATGTGTGGCGG; reverse:
96 CARATGTTAAASACACTATTAGCATA, probe FAM-CAGGTGGAACCTCATCAGGAGATGC-
97 BBQ).

98

99 *Neutralization assay on hybrid HEK293T cells*

100 The day before the experiment, HEK-293T cells expressing ACE2 receptor and the TMPRSS2
101 protease (GeneCopoeia, Rockville, MD, USA) were passaged into 48-well plate (30 000
102 cells/well) in DMEM containing 10 % FBS and 1 % penicillin-streptomycin. On the next day, 35
103 μ M of rucaparib in DMSO was incubated with 4 ng/ μ l RT-equivalent of the pseudovirions for
104 30 minutes in DMEM medium without serum or antibiotics (50 μ l total), in 37 C. For controls,
105 equivalent amount of DMSO was added to the pseudovirions in the absence of rucaparib. The
106 media on the cells were then removed, and the virus-inhibitor medium was complemented with
107 450 μ l DMEM containing 10 % FBS, 1 % penicillin-streptomycin, and thereafter added to the
108 wells (48-well plate). The cells were then incubated for 48 hours in 37 C, after which the media
109 was removed from the wells, and the cells were collected in PBS (400 μ l) for analysis of GFP
110 fluorescence indicating transduction using flow cytometry (FACSCalibur, BD Bioscience,

111 Franklin Lakes NJ, USA), counting 3000 cells/sample. Measurement was carried out in
112 triplicates. Cells were visually inspected for signs of cell death and signs of cell death was not
113 observed in any of the experiments reported.

114

115 *Monocyte differentiation*

116 Peripheral blood mononuclear cells (PBMC) were isolated from three different buffy coat
117 samples received from the Hungarian National Blood Transfusion Service. To separate
118 mononuclear cells, we layered the diluted blood sample in 1:1 ratio with basal RPMI 1640
119 Medium (Lonza, Cat. No: 12-167F) onto the Lymphocyte Separation Medium 1077
120 (PromoCell, Cat. No: CC-44010.) and applied a centrifugation step (400 g, for 30 min, at room
121 temperature with 4/1 acceleration/deceleration). The layer of the mononuclear cells was
122 transferred, washed with PBS (Lonza, Belgium, Cat. No: 17-516F) and centrifuged at 300 g
123 for 10 min at room temperature. Following cell counting 5×10^5 cells per well were seeded to
124 24-well plates (Greiner, Germany, Cat. No: 662160) in complete RPMI 1640 Medium
125 supplemented with Fetal Bovine Serum (Biosera, USA, MO, Cat. No: FB-1350-500) Penicillin-
126 Streptomycin (Lonza, Belgium, Cat. No: DE17-602E) and L-glutamine (Lonza, Belgium, BE-
127 17-605E). To induce macrophage differentiation, we incubated the cells for 5 days at 37 °C,
128 5% CO₂ in a humidified atmosphere.

129

130 *Treatment of differentiated macrophages*

131 In the first part of the experiment, differentiated macrophages were treated in three parallels
132 with the combination of 100 ng/ml LPS (Sigma, USA, MA, Cat. No: L4516) and three different
133 PARP inhibitor molecules diluted in DMSO (Santa Cruz, USA, CA, Cat. No: sc-358801). A 24-
134 hour treatment was applied using 20 µM concentration of Rucaparib and Olaparib and 10 µM
135 concentration of Talazoparib. In all cases 0.1 % DMSO concentration was used as solvent
136 control. The positive control was treated with 0.1 µM and 1 µM Dexamethasone (Teva,
137 Hungary, Cat. No: OGYI-T-6071/03). Following incubation supernatants were collected for
138 further investigation. Monocytes from three donors were accessed and were plotted. The
139 vehicle was 0.01% DMSO.

140 In the second part of the experiment, three parallels of differentiated macrophage cells (three
141 different donors, 30 000 cells/well) were pretreated for 48 hours with 20 nM spike protein
142 (Merck, Germany, Cat. No: AGX818). Rucaparib was added after 48 hours in 5 different
143 concentrations (500 nM, 1 µM, 5 µM, 15 µM, 27 µM) and incubated for 24 hours. The positive
144 control was treated with 1 µM Dexamethasone (Teva, Hungary, Cat. No: OGYI-T-6071/03).
145 Supernatants and cell pellets were collected for further assays. One representative donor is
146 displayed in three biological replicates due to a large heterogeneity of the donor responses.

147

148 *Inflammatory cytokine concentration measurement using Luminex xMAP technology*

149 Luminex Multiplex Immunoassay was performed to determine the following
150 cytokines/chemokine concentrations using customized Milliplex Human
151 Cytokine/Chemokine/Growth Factor Panel A Magnetic Bead Panel (Cat. Nr. HCYTA-60K,
152 Merck Millipore, Darmstadt, Germany): interleukin-10 (IL-10); IL-1 β ; IL-2; IL-6; IL-8; tumor
153 necrosis factor-alpha (TNF- α). Following previous optimizations, the undiluted samples were
154 tested in a blind-fashion and in duplicate. The experiment was performed according to the
155 instructions of the manufacturer. Briefly, 25 μ l volume of each sample, control, and the
156 standard was added to a 96-well plate (provided by the kit) containing 25 μ l of fluorescent-
157 coded, capture antibody-coated beads. After the appropriate washing and incubation periods,
158 biotinylated detection antibodies and streptavidin-PE were added to the plate. 150 μ l volume
159 of drive fluid was added to the wells after the last washing step, and the plate was incubated
160 and read on the Luminex MagPix instrument. Five-PL regression curves were used to plot the
161 standard curves for the analytes by the Belysa 1.1 (Merck KGaA, Darmstadt, Germany)
162 software analyzing the bead median fluorescence intensity. Results are shown in pg/mg.

163

164 *Inflammatory cytokine concentration measurement using the Proquantum kit series*

165 In spike induction experiments IL-6 (A35575), TNF α (A35601) and IL-1 β (A35574) were
166 determined using the respective Proquantum assay kits (ThermoFisher, Waltham, MA, USA)
167 according to the instructions of the manufacturer.

168

169 *Western blotting*

170 Western blots were performed as previously described³. Briefly, cells were lysed directly in
171 pre-heated Laemmli buffer, quantified (BCA protein quantification kit – Pierce, Appleton WI,
172 USA), loaded (20 μ g) in standard 10% SDS-PAGE gels and transferred to nitrocellulose
173 membranes (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% skim milk for
174 30 min and incubated with primary antibodies (anti-p.STAT1 - 1:1000, Cell Signaling #9167;
175 anti-FLAG - 1:1000, Sigma #F1804; anti-tubulin - 1:5000, Abcam #Ab18251) (Cell Signaling,
176 Danves, MA, USA; Abcam, Cambridge, UK) diluted in 5% BSA in TBST buffer, overnight at
177 4°C. Membranes were extensively washed, incubated in appropriate HRP-conjugated
178 secondary antibodies (Sigma), washed, incubated with ECL Prime (Amersham, Amersham,
179 UK) and the signal was detected using a Chemidoc MP Imaging System (Bio-Rad, Hercules,
180 CA, USA). Signals were quantified using ImageJ software.

181

182 *Immunofluorescence staining for ADP-ribose and FLAG*

183 As previously described³, A549 cells, either transduced with empty vector control or lentiviral
184 constructs for FLAG-tagged SARS-CoV-2 macrodomain overexpression were seeded in

185 microscopy-compatible plastic 96-well plates at the density of 10^4 cells/well (Corning, Corning,
186 NY, USA), treated as required, washed with PBS and fixed with 4% EM-grade PFA (EMS,
187 Dornat, Switzerland), which was subsequently quenched twice with 0.1 M glycine and washed
188 in PBS. After permeabilization in 0.2% TritonX-100 in PBS, samples were blocked in 10% FBS
189 in permeabilization solution and incubated with primary antibodies (anti-ADP-ribose - 1:500,
190 Millipore #MABE1016; anti-FLAG - 1:500, Sigma #F1804) (Millipore, Burlington MA, USA) for
191 1h at room temperature in blocking solution. Samples were extensively washed in PBS,
192 incubated with appropriate fluorescently labelled secondary antibodies (Thermo), stained with
193 DAPI (Thermo), washed and maintained in 30% glycerol. For Western blot the seeding density
194 was 2×10^5 cells/well.

195 Fluorescence microscopy images were acquired on a customized TissueFAXS i-Fluo system
196 (TissueGnostics, Wien, Austria) mounted on a Zeiss AxioObserver 7 microscope (Zeiss,
197 Oberkochen, Germany), using 20x Plan-Neofluar (NA 0.5) objective and an ORCA Flash 4.0
198 v3 camera (Hamamatsu, Hamamatsu city, Japan). Acquired images were analyzed using
199 StrataQuest software (TissueGnostics, Wien, Austria).

200 PAR immunofluorescence experiments were repeats were 8, for STAT1 phosphorylation or
201 FLAG immunoblotting repeats were 4. All values were normalized to the IFN γ -treated empty
202 vector control.

203

204 *SARS-CoV-2 spike protein binding assay*

205 Assessment of SARS-CoV2 RBD and hACE2 binding inhibition was performed using RayBio®
206 COVID-19 spike-ACE2 binding assay kit (CoV-SACE2-1, RayBiotech Inc.,
207 https://www.raybiotech.com/covid-19-spike-ace2-binding-assay-kit-en/?variation_id=107121).
208 Recombinant SARS-CoV-2 spike RBD protein coated wells were treated with the compounds
209 (rucaparib, stenoparib, olaparib) in the range of concentration from 1 μ M up to 500 μ M, then
210 incubated for 16 h at 4 °C. Next, the recombinant hACE2 protein was added and the protocol
211 provided by the manufacturer was followed. In brief: unbound hACE2 protein was removed by
212 washing, and binding was assessed based on HRP-conjugated IgG in the presence of
213 3,3',5,5'-tetramethylbenzidine (TMB) substrate. The HRP-conjugated IgG binds to the hACE2
214 protein and reacts with the TMB solution, producing a blue color that is proportional to the
215 amount of bound hACE2. The HRP-TMB reaction is halted with the addition of the Stop
216 Solution, resulting in a blue-to-yellow color change. The intensity of the yellow color is then
217 measured by absorbance at 450 nm with a microplate reader SpectraMax® iD5 (Molecular
218 Devices, LLC., San Jose, CA, USA). Data points were obtained as average of duplicates and
219 IC₅₀-curves were fitted by non-linear regression using GraphPad Prism.

220

221 *Molecular modeling*

222 We have used the FTMap protein mapping algorithm to identify possible binding sites on the
223 protein-protein interaction surface of the spike protein receptor-binding domain (RBD) vs. the
224 human ACE2 receptor^{5,6}. Briefly, the FTMap method distributes small organic probe molecules
225 on a dense grid defined on the protein surface, finds the most favorable positions for each
226 probe type, and identifies preferred binding hotspots as regions that bind multiple probe
227 clusters. Here, we have used the experimentally determined structures of the ACE2-RBD
228 complex for the B.1.5 (“Wuhan”, PDB ID: 6M0J)⁷, B.1.617.2 („Delta”, PDB ID: 7WBQ) and
229 B.1.1.529 („Omicron”, PDB ID: 7WBP) variants⁸, and observed exactly one binding hotspot at
230 the protein-protein interaction surface of all three variants, characterized by the residues 493-
231 498, with further sidechains R403, E406, Y449, Y453, N501 and Y505 in the vicinity. After
232 preparing the structure of rucaparib with LigPrep⁹, ligand docking was carried out with the
233 single precision (SP) mode of Glide^{10,11}, and the binding mode was visualized with Maestro.

234

235 *Sequence homology alignment*

236 spike protein amino acid sequence was retrieved from <https://viralzone.expasy.org/9556>.
237 Sequences were retrieved for the wild type (<https://www.uniprot.org/uniprot/P0DTC2>), the
238 alpha (<https://www.ncbi.nlm.nih.gov/protein/QWE88920>), the beta
239 (<https://www.ncbi.nlm.nih.gov/protein/QRN78347>), the gamma
240 (<https://www.ncbi.nlm.nih.gov/protein/QVE55289>), the delta
241 (<https://www.ncbi.nlm.nih.gov/protein/QWK65230>), the omicron BA.1
242 (<https://www.ncbi.nlm.nih.gov/protein/UFO69279.1?report=fasta>), the omicron BA.2
243 (<https://www.ncbi.nlm.nih.gov/protein/UJE45220.1?report=fasta>), and the epsilon
244 (<https://www.ncbi.nlm.nih.gov/protein/QQM19141>) variants. The relevant parts of the
245 sequence were aligned using the ClustalW algorithm ([https://www.genome.jp/tools-](https://www.genome.jp/tools-bin/clustalw)
246 [bin/clustalw](https://www.genome.jp/tools-bin/clustalw)). All sites were accessed the 1st April 2022.

247 On the figure conserved amino acids as compared to the wild type variant are in green. The
248 non-conserved amino acids are represented in red.

249

250 *Expression and purification of the receptor binding domain of the spike protein*

251 The receptor-binding domain (RBD) of the SARS-CoV-2 virus spike protein (³¹⁹Arg-⁵⁴¹Phe)
252 (Wuhan-Hu-1) was used in the experiments. Suspension HEK-293 cells stably expressing the
253 RBD secreted to the culture media were created by the Sleeping Beauty transposon method
254 using the p10-IRES2-eGFP vector construct as in a different application, described previously
255 [31].

256 The RDB sequence, as produced by Amanat et al. [32], was inserted to the Sleeping Beauty
257 transposon plasmid. The sequence on the N-terminal includes a signal peptide responsible for
258 the secretion of the protein to the culture media and 6x His tag was introduced on the C-

259 terminal. Shaken cultures of suspension-adapted HEK293 cells were grown in a serum-free
260 FreeStyle 293 expression medium (Gibco, Waltham, MA, USA, Cat. no. 12338018) incubated
261 at 37°C and 5% CO₂, shaken at 100 rpm. The cells were sub-cultured every 3-4 days with
262 seeding densities of 2 ×10⁵ cells/mL to promote cell growth and scale-up. The RBD was
263 produced in a 300 mL shake flask cell culture. Cells were removed after 5-6 days by
264 centrifugation (20 min, 1000 rpm, Rotanta 460R, Hettich, Kirchleugern, Germany). The
265 purification of RBD was accomplished by immobilized nickel ion affinity chromatography. The
266 supernatant was loaded into a 5 mL HisTrap HP column (GE Healthcare, Chicago, IL, USA),
267 which was connected to an FPLC system (ÄKTA pure™, GE Healthcare, Chicago, IL, USA).
268 Protein bound to the column was eluted by imidazole (200 mM, pH 7.4). The protein-containing
269 fraction was concentrated while the elution buffer was replaced by phosphate buffer (pH 6.8)
270 using a centrifugal filter device. Centrifugation (Rotanta 460R, Hettich, Kirchleugern, Germany)
271 was performed at 4000 g for 20 minutes using a 30 KDa MWCO filter (Vivacell 100, Sartorius,
272 Göttingen, Germany). The purity of the produced protein was confirmed by SDS-PAGE and
273 the protein concentration was determined by UV-Vis spectroscopy at 280 nm.

274

275 *Nuclear Magnetic Resonance (NMR)-based investigation of spike-rucaparib interaction*

276 Solution phase NMR experiments were performed under the following conditions.

277 The RBD of spike (~ 28 kDa) + rucaparib camsylate assay mixture contained 33 μM RBD (in
278 540 μL) and 1 mM rucaparib (dissolved in DMSO-d₆ in 20 μL) + 10% D₂O for lock in sodium-
279 phosphate buffer (0.2 M, pH 6.8). Rucaparib was in ~30 fold excess. The RBD and rucaparib
280 were assessed also without the other partner under the same conditions as references.

281 Bruker Avance Neo 700 MHz spectrometer (Bruker, Billerica, MA, USA) equipped with a
282 Prodigy TCI cryoprobe was used. Experiments were run at 298K temperature and 10% D₂O
283 was added to the solution for stabilizing the magnetic field via the ²H lock channel. Typical 90
284 degree ¹H pulse duration was 11.5 μs. The residual DMSO-d₆ signal (2.59 ppm) was used as
285 ¹H chemical shift reference. The NMR verification of the structure of rucaparib-camphor
286 sulfonic acid (camsylate) salt was carried out in pure DMSO-d₆ solvent and yielded a full
287 assignment of all ¹H and ¹³C signals (spectra not shown). The assignments of aromatic (H15,
288 H16, H18,H19) and olefinic (H11, H13) protons could be easily transferred to the buffer,
289 containing rucaparib with or without the RBD protein. Excitation sculpting water suppression
290 ¹H-NMR spectra using manufacturers 'zgesfpgp' pulse sequence was applied (**FigS1G**)¹². The
291 drug ligand signal appear as sharp signals while the protein signals are weak and broad (due
292 to concentration and MW differences). A relatively strong and well separated RBD signal at
293 0.4 ppm was selected for selective irradiation in STD-NMR (saturation transfer difference)
294 experiments (weaker RBD signals below 0 ppm were also tested, and gave observable, but
295 weaker responses)¹³⁻¹⁶. For STD we used manufacturers 'stddiffgp19.3' pulse sequence with

296 watergate water suppression¹⁷. Selective saturation was achieved using a series of 50 ms
297 selective 90 degree Gaussian pulses, resulting in 2000 ms total irradiation time. The reference
298 experiment was carried out identically, except that an off resonance irradiation at -40 ppm was
299 applied. A total of 12160 scans interrupted with 2s relaxation delays were coadded in both the
300 on-resonance and the off-resonance (reference) experiments yielding one day total experiment
301 time. In the difference spectrum of the two experiments (**FigS1H**) the irradiated broad RBD
302 signal is the strongest among protein signals, while the six protons of rucaparib ligand-probably
303 closest to the binding site- gave the strongest responses. In the control experiment with no
304 RBD protein, the Rucaparib did not show the characteristic difference signals. An independent
305 corroboration of Rucaparib binding to RBD was carried out with the (non-selective) transferred
306 NOESY¹⁸ experiment ('noesygpph19' pulse sequence). Again, the fingerprint signals gave
307 cross-peaks with the same sign relative to the diagonal in the 2D NOESY map while they were
308 missing in a sample without the protein.

309

310 *Transcription factor activation assay*

311 Human peripheral blood mononuclear cells were differentiated to macrophages as described
312 above. Cells were induced with the spike protein of SARS-CoV-2 (20 nM, 24 hours) and were
313 treated with rucaparib in the concentrations indicated. Cell were then scraped whole cell
314 lysates were used to perform transcription factor binding assays using TransAm kits
315 (ActiveMotif Tegernheim, Bayern, Germany) similar to¹⁹. Stat family (Cat. No. 42296) was used
316 in the study.

317

318 *Statistical analyses*

319 All experiments were repeated on at least three separate occasions, often with multiple parallel
320 replicates processed on the same day, but treated as independently as possible. All graphs
321 and statistical analyses were generated using GraphPad Prism v.8.0.1 software.

322 Numerical values are presented as the average \pm SD. Normality was checked. . *, **, ***
323 represent statistically significant differences between the controls/vehicle-treated cells and
324 patients/treated cells at $p < 0.05$, $p < 0.01$ and $p < 0.001$, respectively.

325 Two-tailed Student's t-test on Figure 1 panel C and D

326 One-way ANOVA was used on Figure 1 panel B, Supplementary Figure 1 panels A, C, E and
327 F, in the post-hoc test all treatments were compared to the control.

328 One-way ANOVA was used on Figure 2 E and F and throughout Supplementary Figure 2,
329 followed by a post-hoc test comparing all samples to the LPS or spike-treated groups.

330

331

332

333 **Captions to supplementary Figures**

334 **Supplementary Figure 1. Olaparib and talazoparib do not block SARS-CoV-2 infection**
335 **and rucaparib does not inhibit the macrodomain of SARS-CoV-2**

336 **(A)** The antiproliferative and toxic effects of olaparib and talazoparib were tested in Vero E6
337 cells infected with of B.1.5 variant SARS-CoV-2. **(B)** Predicted binding mode of rucaparib
338 (green) at the protein-protein binding surface of the SARS-CoV2 RBD (fawn), overlaid on the
339 position of the ACE2 receptor (transparent blue). **(C-F)** A549 cells, either transduced with
340 empty vector control (e.v.) or lentiviral constructs for FLAG-tagged SARS-CoV-2 macrodomain
341 overexpression (MD) were treated with either vehicle or different combinations of 100U IFN γ ,
342 500 nM or 20 μ M rucaparib for 24 hours, as shown. ADP-ribosylation was detected by
343 immunofluorescence (C) and STAT1 phosphorylation, FLAG or tubulin levels were determined
344 by immunoblotting (D-F). All values were normalized to the IFN γ -treated e.v. control. **(G)**
345 Excitation sculpting water suppression 1 H-NMR spectra using the manufacturer's 'zgesfpgp'
346 pulse sequence. Blue: no RBD, red: with RBD. **(H)** Whole difference spectrum of the Rucaparib
347 alone (blue), Rucaparib with RBD (green) and buffer alone (red). The red rectangle marks the
348 region displayed on **Fig.2B**.

349

350 **Supplementary Figure 2. Rucaparib inhibits the LPS-induced overexpression of IL-8 and**
351 **IL-10**

352 **(A)** Human primary monocyte-derived macrophages were challenged with LPS (100 ng/mL,
353 24 hours) and indicated interleukins were determined. Three individual donors are displayed.
354 **(B)** A549 cells were induced with poly(I:C) and STAT1 phosphorylation was determined as
355 described in Materials and Methods. **(C)** Stat1, 3, 5A and 5B activation was determined in
356 human macrophages using the TransAM kit as described in the Materials and methods. One
357 donor is displayed.

358

Supplementary Table 1. Patient characteristics

For comparing age, normality was checked and two-sided, non-paired t-test was applied. AVG – average, CVE – cardiovascular event, DCM – dilated cardiomyopathy, F – female, IHD – ischaemic heart disease, GERD - Gastroesophageal reflux disease, M – male, n.s. – not significant

Control patients			COVID-19 patients		
Patient identifier	Sex	Age	Patient identifier	Sex	Age
1	F	66-70	1	M	56-60
2	F	86-90	2	F	86-90
3	F	81-85	3	F	81-85
4	M	86-90	4	F	61-65
5	M	66-70	5	F	81-85
6	F	86-90	6	M	56-60
7	M	56-60	7	M	61-65
8	F	76-80	8	F	56-60
9	M	81-85	9	F	76-80
10	M	65-70	10	M	61-65
			11	M	61-65
			12	M	76-80
			13	F	71-75
			14	M	61-65
			15	M	61-65
AVG	10 patients 50% M 50% F	77.1 ± 10.5 yrs	15 patients	53,3% M 46,7% F	69 ± 10.9 yrs ^{ns}

Supplementary Table 2. Conditions for immunohistochemistry

Abbreviation: CC1 - ULTRA Cell Conditioning Solution (Ventana Medical Systems, Oro Valley, AZ, USA)

Primary Antibody					Antigen retrieval: HIER		Immunohistochemical stainers			
Antibody name	Vendor	Host	Dilution factor	Incubation time/temp.	Method	Time/Temp.	Visualization system	Enhancement	Counterstain	Staining Platform
Anti-4 Hydroxynonenal antibody (ab46545)	Abcam	rabbit polyclonal	1/400	32'/37 °C	CC1, pH8,5	36' ,95°C;	UltraView Universal DAB Detection Kit	CuSO4	Hematoxylin II	VENTANA BenchMark ULTRA
Poly(ADP-ribose) monoclonal antibody (10H). (ALX-804-220-R100)	Enzo	mouse monoclonal	1/2000	32'/37 °C		64' ,95°C;				
SARS-CoV-2 spike Glycoprotein S1 ab/ (ab275759)	Abcam	rabbit polyclonal	1/1000	1h /37 °C		56' ,100°C;				

References

1. Csonka, T., *et al.* *Folia Neuropathologica* **54**, 114-126 (2016).
2. Kovács, P., *et al.* *Cancers (Basel)* **11**, 1255 (2019).
3. Russo, L.C., *et al.* *Journal of Biological Chemistry* **297**, 101041 (2021).
4. Mahdi, M., Szojka, Z., Mótyán, J.A. & Tózsér, J. *Journal of virology* **92**(2018).
5. Kozakov, D., *et al.* *Nat Protoc* **10**, 733-755 (2015).
6. Brenke, R., *et al.* *Bioinformatics* **25**, 621-627 (2009).
7. Lan, J., *et al.* *Nature* **581**, 215-220 (2020).
8. Han, P., *et al.* *Cell* **185**, 630-640.e610 (2022).
9. Sastry, G.M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. *Journal of computer-aided molecular design* **27**, 221-234 (2013).
10. Friesner, R.A., *et al.* *J Med Chem* **47**, 1739-1749 (2004).
11. Halgren, T.A., *et al.* *J Med Chem* **47**, 1750-1759 (2004).
12. Hwang, T.L. & Shaka, A.J. *Journal of Magnetic Resonance, Series A* **112**, 275-279 (1995).
13. Mayer, M. & Meyer, B. *Journal of the American Chemical Society* **123**, 6108-6117 (2001).
14. Kövér, K.E., Groves, P., Jiménez-Barbero, J. & Batta, G. *J Am Chem Soc* **129**, 11579-11582 (2007).
15. Viegas, A., Manso, J., Nobrega, F.L. & Cabrita, E.J. *Journal of Chemical Education* **88**, 990-994 (2011).
16. Unione, L., *et al.* *Angewandte Chemie International Edition* **61**, e202201432 (2022).
17. Piotto, M., Saudek, V. & Sklenář, V. *Journal of Biomolecular NMR* **2**, 661-665 (1992).
18. Meyer, B., Weimar, T. & Peters, T. *Eur J Biochem* **246**, 705-709 (1997).
19. Brunyanszki, A., *et al.* *Journal of Investigative Dermatology* **130**, 2629-2637 (2010).